Losartan + Hidroclorotiazida Eplit Dosage

What is the dose of your medication?

Dosage of Losartan + Hidroclorotiazida Eplit in details

Losartan + Hidroclorotiazida Eplit Dosage

Generic name: Losartan (Losartan + Hidroclorotiazida Eplit) potassium 50mg, Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) 12.5mg

Dosage form: tablet, film coated

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Hypertension

The usual starting dose of Losartan + Hidroclorotiazida Eplit is 50/12.5 (Losartan (Losartan + Hidroclorotiazida Eplit) 50 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losartan + Hidroclorotiazida Eplit) 100 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) 25 mg) once daily as needed to control blood pressure.

Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartan + Hidroclorotiazida Eplit) 50 mg monotherapy with Losartan + Hidroclorotiazida Eplit 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losartan + Hidroclorotiazida Eplit 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Eplit 100/25 once daily.

Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartan + Hidroclorotiazida Eplit) 100 mg monotherapy with Losartan + Hidroclorotiazida Eplit 100/12.5 (Losartan (Losartan + Hidroclorotiazida Eplit) 100 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartan + Hidroclorotiazida Eplit 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Eplit 100/25 once daily.

Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losartan + Hidroclorotiazida Eplit 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losartan + Hidroclorotiazida Eplit 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartan + Hidroclorotiazida Eplit 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Eplit 100/25 once daily.

Hypertensive Patients with Left Ventricular Hypertrophy

In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losartan + Hidroclorotiazida Eplit) potassium, initiate treatment with Losartan + Hidroclorotiazida Eplit 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losartan + Hidroclorotiazida Eplit 100/12.5, followed by Losartan + Hidroclorotiazida Eplit 100/25. For further blood pressure reduction add other antihypertensives.

More about Losartan + Hidroclorotiazida Eplit (Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) / Losartan (Losartan + Hidroclorotiazida Eplit))

Consumer resources

Professional resources

Related treatment guides

What other drugs will affect Losartan + Hidroclorotiazida Eplit?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Losartan + Hidroclorotiazida Eplit, especially:

This list is not complete. Other drugs may interact with Losartan + Hidroclorotiazida Eplit, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Losartan + Hidroclorotiazida Eplit interactions

Agents Increasing Serum Potassium

Coadministration of Losartan (Losartan + Hidroclorotiazida Eplit) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.

Lithium

Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losartan + Hidroclorotiazida Eplit and lithium.

Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors

Losartan (Losartan + Hidroclorotiazida Eplit) Potassium

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losartan + Hidroclorotiazida Eplit)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losartan + Hidroclorotiazida Eplit) and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losartan + Hidroclorotiazida Eplit), may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit)

The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartan + Hidroclorotiazida Eplit and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.

In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losartan + Hidroclorotiazida Eplit), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit), Losartan (Losartan + Hidroclorotiazida Eplit), and NSAID therapy.

Dual Blockade Of The Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losartan + Hidroclorotiazida Eplit) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losartan + Hidroclorotiazida Eplit) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

Closely monitor blood pressure, renal function, and electrolytes in patients on Losartan + Hidroclorotiazida Eplit and other agents that affect the RAS.

Do not coadminister aliskiren with Losartan + Hidroclorotiazida Eplit in patients with diabetes. Avoid use of aliskiren with Losartan + Hidroclorotiazida Eplit in patients with renal impairment (GFR < 60 mL/min).

The Use Of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) With Other Drugs

When administered concurrently, the following drugs may interact with thiazide diuretics :

Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.

Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) and the resin such that Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Eplit) + Hidroclorotiazida Eplit) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.

References

  1. DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. FDA/SPL Indexing Data. "JMS50MPO89: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Losartan + Hidroclorotiazida Eplit are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losartan + Hidroclorotiazida Eplit. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 1 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved